Ulipristal Shortage: What Providers and Prescribers Need to Know in 2026

As a prescriber, you know that timing is everything when it comes to emergency contraception. Ulipristal Acetate (Ella) — the only prescription oral emergency contraceptive effective for up to 120 hours post-intercourse — offers a critical clinical advantage over levonorgestrel-based options. But if your patient can't fill the prescription, that advantage disappears.

This article provides a clinical and operational overview of Ulipristal availability in 2026, including current supply status, prescribing considerations, cost and access barriers, and tools to help your patients get the medication they need.

Current Supply Status

As of early 2026, Ulipristal Acetate is not listed in a formal FDA drug shortage. The drug is being manufactured by Afaxys (U.S. marketer of brand-name Ella) and is available through standard pharmaceutical distribution channels. A generic version, Logilia (Ulipristal Acetate 30 mg), is also available on the U.S. market.

However, the practical availability picture is more nuanced. Many retail pharmacies do not routinely stock Ella or its generic due to low prescription volume. This creates significant access barriers, particularly in rural and underserved areas.

Timeline: How We Got Here

Understanding the current availability landscape requires some context:

• 2010: FDA approves Ulipristal Acetate (Ella) for emergency contraception in the U.S.
• 2010–2020: Ella remains a niche prescription product with modest market penetration compared to OTC levonorgestrel
• 2018: European Medicines Agency issues liver safety warnings for Esmya (Ulipristal for fibroids), which raised general awareness of the drug's safety profile — though the emergency contraception dose (30 mg single dose) was not implicated
• 2020–2023: COVID-19 pandemic disrupts healthcare access broadly; telehealth emerges as a key prescribing pathway for EC
• 2024–2025: Generic Logilia enters U.S. market, improving pricing but not uniformly improving pharmacy stocking
• 2026: No formal shortage, but persistent pharmacy-level stocking gaps remain the primary barrier to patient access

Prescribing Implications

When prescribing Ulipristal Acetate, keep the following clinical considerations in mind:

Indications and Dosing

Ulipristal Acetate 30 mg is indicated as a single oral dose for emergency contraception within 120 hours (5 days) of unprotected intercourse or known/suspected contraceptive failure. Unlike levonorgestrel, it maintains consistent efficacy throughout the full 5-day window.

Contraindications

• Known or suspected pregnancy
• Severe hepatic impairment
• Hypersensitivity to ulipristal acetate or excipients
• Severe asthma insufficiently controlled by oral glucocorticoids (due to antiglucocorticoid activity)

Drug Interactions

Ulipristal is metabolized by CYP3A4. Concomitant use with strong CYP3A4 inducers (Rifampicin, Phenytoin, Carbamazepine, St. John's Wort) may reduce efficacy and is not recommended. CYP3A4 inhibitors (Ritonavir, Ketoconazole) may increase plasma levels. Importantly, Ulipristal may reduce the effectiveness of hormonal contraceptives, and vice versa — advise patients to use barrier methods until their next menstrual period. For detailed interaction data, see Ulipristal Drug Interactions.

Special Populations

Ulipristal has not been studied in patients under 18. It is embryotoxic in animal studies — pregnancy must be excluded before administration. Breastfeeding should be avoided for 7 days after the dose, as the drug is excreted in breast milk.

The Availability Picture

The core challenge is not supply — it's pharmacy stocking decisions. Key factors:

• Chain pharmacies use centralized inventory algorithms that may deprioritize low-volume items like Ella
• Independent pharmacies may be more responsive to local demand but may not proactively stock EC products
• Rural and conservative regions have particularly low stocking rates
• Planned Parenthood and Title X clinics often maintain on-site stock

This inconsistency means that even when you write a timely prescription, your patient may face delays of 24–48 hours while the pharmacy orders the medication — potentially pushing them outside the efficacy window.

Cost and Access Considerations

Cost should not be a barrier for most patients, but awareness of pricing helps set expectations:

• Brand Ella: $50–$90 cash price
• Generic Logilia: $35–$55 cash price
• With discount cards: As low as $39.90 (SingleCare)
• With insurance (ACA plans): Typically $0 copay under the contraceptive coverage mandate
• Medicare Part D: Generally does not cover EC
• Medicaid: Coverage varies by state

For patients facing cost barriers, direct them to savings resources for Ulipristal or our provider guide to helping patients save.

Tools and Resources for Providers

Several tools can help you and your patients navigate availability challenges:

Medfinder for Providers

Medfinder allows providers and patients to search for pharmacies that currently stock a given medication. You can direct patients to check availability before leaving your office, or integrate this step into your prescribing workflow.

Telehealth Prescribing Platforms

If your practice setting doesn't support same-day prescribing (e.g., you're consulted after hours), consider directing patients to telehealth services that specialize in reproductive health and can prescribe and ship Ella directly. Platforms like Wisp, Nurx, and PRJKT RUBY offer expedited fulfillment.

Advance Prescriptions

Consider providing advance prescriptions for Ella to patients who are at risk of contraceptive failure or who express interest in having EC available proactively. This gives patients time to fill the prescription before an emergency arises.

Clinic-Based Dispensing

If your practice or health system is able to stock and dispense Ella on-site, this eliminates the pharmacy stocking barrier entirely. Title X-funded clinics and Planned Parenthood locations already follow this model.

Looking Ahead

Several trends may improve Ulipristal access in the coming years:

• Generic market expansion: Additional generic manufacturers may enter the market, further improving stocking and reducing cost
• Telehealth normalization: Post-pandemic telehealth infrastructure makes remote prescribing and direct-to-patient shipping increasingly viable
• Policy advocacy: Ongoing discussions about moving Ella to OTC status could dramatically improve access, though this remains under regulatory review
• Inventory transparency tools: Platforms like Medfinder are closing the information gap between prescribers and pharmacy inventory

Final Thoughts

Ulipristal Acetate remains the gold standard for oral emergency contraception beyond 72 hours. While there is no formal drug shortage in 2026, the persistent gap between prescribing and pharmacy-level availability continues to be a clinical frustration. By combining awareness of the availability landscape with practical tools — advance prescribing, telehealth referrals, Medfinder, and clinic-based dispensing — providers can help ensure their patients actually receive the medication they prescribe.

For more clinical information, see How to Help Your Patients Find Ulipristal in Stock: A Provider's Guide.